Nuvilex (PMCB) Stock Price, News & Analysis

Company Overview

Nuvilex, Inc. (NASDAQ: PMCB) is a clinical-stage biopharmaceutical company focused on the development of cell-based therapies for the treatment of various cancers. The company’s core technology revolves around the encapsulation of live cells within proprietary biocompatible polymers, enabling localized delivery of therapeutic agents directly to tumor sites. This approach is designed to maximize anti-tumor activity while minimizing systemic side effects commonly associated with conventional chemotherapy.

Within its pipeline, Nuvilex is developing multiple lead candidates aimed at solid tumors that are historically difficult to treat. The company’s flagship product candidate utilizes encapsulated live cells to convert an administered prodrug into an active chemotherapy agent in situ, offering a novel mechanism to target pancreatic, liver and ovarian tumors. Preclinical studies have demonstrated promising safety and efficacy profiles, and the firm is preparing for upcoming clinical trials in collaboration with academic medical centers.

Founded in 2000 under the name Biovax, Inc., the company rebranded as Nuvilex in 2017 to reflect its emphasis on next-generation oncology platforms. Headquartered in Philadelphia, Pennsylvania, Nuvilex operates research and manufacturing facilities in the United States while engaging in strategic partnerships across Europe and Asia to expand clinical development and regulatory support. These alliances enable the company to leverage international expertise in cell therapy manufacturing and to pursue global trial sites.

Nuvilex’s management team combines seasoned executives from the biopharmaceutical and biotechnology sectors. The company’s board and leadership group bring extensive experience in drug development, regulatory affairs and corporate governance. Under their direction, Nuvilex continues to advance its encapsulation technology through IND-enabling studies, with the goal of delivering differentiated cancer therapies to patients facing high-unmet medical needs.

Key Stats

• Today's Range: $1.08 to $1.15
• 50-Day Range: $1.00 to $1.14
• 52-Week Range: $1.00 to $2.42
• Volume: 31,511 shs
• Average Volume: 19,817 shs
• Market Capitalization: $7.68 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Nuvilex Stock Analysis - MarketRank™

Nuvilex scored higher than 60% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Nuvilex.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Nuvilex is 1.51, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 26.70.

Price to Earnings Ratio vs. Sector

The P/E ratio of Nuvilex is 1.51, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 28.61.

Price to Book Value per Share Ratio

Nuvilex has a P/B Ratio of 0.34. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.29% of the float of Nuvilex has been sold short.

Short Interest Ratio / Days to Cover

Nuvilex has a short interest ratio ("days to cover") of 1.5, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Nuvilex has recently decreased by 16.43%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Nuvilex does not currently pay a dividend.

Dividend Growth

Nuvilex does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.29% of the float of Nuvilex has been sold short.

Short Interest Ratio / Days to Cover

Nuvilex has a short interest ratio ("days to cover") of 1.5, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Nuvilex has recently decreased by 16.43%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 4.4 / 5
• News Sentiment: N/A

News Sentiment

Nuvilex has a news sentiment score of 1.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.97 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Nuvilex this week, compared to 0 articles on an average week.

Search Interest

1 people have searched for PMCB on MarketBeat in the last 30 days.

MarketBeat Follows

1 people have added Nuvilex to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Nuvilex insiders have not sold or bought any company stock.

Percentage Held by Insiders

10.20% of the stock of Nuvilex is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 34.24% of the stock of Nuvilex is held by institutions.

PMCB Stock Analysis - Frequently Asked Questions

How have PMCB shares performed this year?

Nuvilex's stock was trading at $1.57 on January 1st, 2025. Since then, PMCB shares have decreased by 28.7% and is now trading at $1.12.

How were Nuvilex's earnings last quarter?

Nuvilex Inc. (NASDAQ:PMCB) released its quarterly earnings results on Monday, March, 17th. The company reported ($0.10) EPS for the quarter.

How do I buy shares of Nuvilex?

Shares of PMCB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Nuvilex own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Nuvilex investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), ASML (ASML), GE Aerospace (GE), Oracle (ORCL) and Nokia (NOK).

Company Calendar

• Last Earnings: 3/17/2025
• Today: 7/16/2025
• Next Earnings (Estimated): 8/11/2025
• Fiscal Year End: 4/30/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:PMCB
• CIK: 1157075
• Web: pharmacyte.com
• Phone: 917-595-2850
• Fax: 917-595-2851
• Employees: 4
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): $0.74
• Trailing P/E Ratio: 1.48
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $330 thousand
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: 0.51%
• Return on Assets: 0.35%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 14.21
• Quick Ratio: 14.21

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $3.27 per share
• Price / Book: 0.33

Miscellaneous

• Outstanding Shares: 6,860,000
• Free Float: 6,164,000
• Market Cap: $7.51 million
• Optionable: Optionable
• Beta: -0.42